2019:BMS buys celgene for 74b. 2024 BMS market cap: 89b

Discussion in 'Bristol-Myers Squibb' started by anonymous, May 1, 2024 at 6:44 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    The investment community did'nt realize there were So many Texans on Wall St...
     

  2. anonymous

    anonymous Guest

    having worked at both companies, I can say unequivocally that Celgene people were smart and got things done. People were excited to be there. BMS is bloated, all talk, no action. Ridiculously cumbersome processes at every turn. Lifers who can’t do things differently and who undermine efficiency all the time.
     
  3. anonymous

    anonymous Guest

    You just described Big Pharma as a whole.
     
  4. anonymous

    anonymous Guest

    BMS lifers with talent and time for a career change all left. Celgene is now unencumbered and free to dazzle with innovative style!
    We look forward to
     
  5. anonymous

    anonymous Guest

    BMS lifers with talent and time for a career change all left. Celgene is now unencumbered and free to dazzle with innovative style!
    The scientific and investment worlds look forward to being dazzled.
     
  6. anonymous

    anonymous Guest

    100% - and at CELG we got paid for performance
     
  7. anonymous

    anonymous Guest

    My Celgene team in the NE runs circles around their BMS counterparts!
     
  8. anonymous

    anonymous Guest

     
  9. anonymous

    anonymous Guest

    I worked at CELG I&I and worked at Amgen INBU for a year. I left. Celgene ruined me to all other experiences. As a rep, I got paid to perform. No silly business about faking calls for the KPI dashboard. No doing programs unless I thought they were needed. No silly teleconferences 3x a week for 4DX or ACT Promotion fakery. I got paid to haul freight.

    I did and as an Executive Rep, I got $75k a year in equity and I made >$125k a year in IC every single year. I took trips to Spain, Italy, France, Bali and was scheduled to go to Greece when Amgen ruined the fantasy.

    I can't say anything good or bad about BMY, but I left Amgen because it's cumbersome bureaucracy and its laser focus on activity. All leadership cares about is stuffing the KPI dashboard with numbers that look good to Thousand Oaks.

    Culture is king.
     
  10. anonymous

    anonymous Guest

    A simple concept that Big Pharma forgot long ago. We are in sales. If you want to motivate the field, show me the money. There’s a total imbalance when the CEO is making 18-20 a year and reps are getting scraps. If they want employees invested they need to rethink how we are being paid.
     
  11. anonymous

    anonymous Guest

    ...and the stock trades in the $40's/share. Maybe Celgenies should stop running in circles?
     
  12. anonymous

    anonymous Guest

    RIP Charlie & BMS (be-a-mess).
     
  13. anonymous

    anonymous Guest

    Schering Plough was like this too, if you performed, they paid. Do companies like these exist anymore?
     
  14. anonymous

    anonymous Guest

    I’ve been a leader in both organizations, and I can tell you that my Celgene people are better.
     
  15. anonymous

    anonymous Guest

    43$/share says it ain't showing.
     
  16. anonymous

    anonymous Guest

  17. anonymous

    anonymous Guest

  18. anonymous

    anonymous Guest

    Not my Celgene team’s fault
     
  19. anonymous

    anonymous Guest

    it is showing because the Celgene people are gone
     
  20. anonymous

    anonymous Guest

    Left a couple of your Legends in C-Suite. Please come pick them up.